消化性溃疡药物市场规模、份额和成长分析（按药物类型、溃疡类型、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，消化性溃疡药物市场规模将达到 49.3 亿美元，到 2025 年将达到 51 亿美元，到 2033 年将达到 67.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 3.5%。

全球消化性溃疡药物市场正稳定成长，主要驱动因素是消化性溃疡疾病的广泛流行，影响着全球数百万人口。人口老化以及吸烟、酗酒等不健康生活方式的增加是关键驱动因素。此外，医疗技术的创新和新药製剂的研发也进一步加速了市场扩张。然而，学名药的出现和替代治疗方法的兴起也带来了挑战。儘管存在这些障碍，但人们对早期诊断和有效治疗必要性的认识不断提高，预计将显着增强市场动态，并促进消化性溃疡药物的持续发展和广泛应用。

消化性溃疡药物市场驱动因素

推动消化性溃疡药物市场成长的关键因素之一是全球消化性溃疡发生率的上升。这种消化系统疾病影响大量人群，导致对有效治疗方案的需求不断增长。不良的生活习惯、压力增加以及非类固醇消炎剂（NSAIDs）的广泛使用等因素都与消化性溃疡发生率的上升密切相关。由此产生的对有效药物日益增长的需求，不仅凸显了解决这个健康问题的重要性，也推动了整个市场的扩张，因为医疗保健机构正努力满足患者的需求。

限制消化性溃疡治疗市场的因素

全球消化性溃疡药物市场面临的一大限制因素是各种替代治疗方法的存在。许多患者选择非药物疗法，例如生活方式调整、饮食改变和自然疗法，这些疗法被认为对控制消化性溃疡有效。这种替代疗法的趋势可能会降低对传统消化性溃疡药物的需求。此外，长期服用这些药物可能带来的副作用和健康风险，可能会进一步降低患者和医疗保健提供者对药物的依赖，最终影响市场趋势和整个行业的成长。

消化性溃疡治疗市场趋势

全球消化性溃疡治疗市场的一个显着趋势是，质子帮浦阻断剂（PPI）作为第一线治疗药物的受欢迎程度日益提高。这项转变主要是由于PPI相比其他疗法具有更优的疗效和更佳的安全性。 PPI能显着抑制胃酸分泌，从而长期缓解症状并促进溃疡癒合。此外，药物製剂的不断改进提高了生物利用度和患者依从性，进一步增强了PPI的吸引力。预计此药物需求的成长趋势将显着影响消化性溃疡治疗市场的需求趋势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球消化性溃疡药物市场规模（按药物类型和复合年增长率划分）（2026-2033 年）

• 质子帮浦阻断剂
• H2受体拮抗剂
• 抗生素
• 其他的

全球消化性溃疡药物市场规模（依溃疡类型及复合年增长率划分）（2026-2033 年）

• 胃溃疡
• 十二指肠溃疡
• 食道溃疡

全球消化性溃疡药物市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 零售药房
• 网路药房

全球消化性溃疡治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• AstraZeneca plc.（United Kingdom）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc.（United Kingdom）
• Sanofi SA（France）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Bristol-Myers Squibb Company（United States）
• Mylan NV（Netherlands）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Ltd.（India）
• Lupin Ltd.（India）
• Zydus Cadila（India）

结论与建议

Peptic Ulcer Drugs Market size was valued at USD 4.93 Billion in 2024 and is poised to grow from USD 5.1 Billion in 2025 to USD 6.71 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The global market for peptic ulcer drugs is experiencing consistent growth, primarily influenced by the widespread prevalence of peptic ulcer disease, which impacts millions globally. Key drivers include an aging population and a rise in unhealthy lifestyle choices, such as smoking and excessive alcohol consumption. Moreover, innovations in medical technology and the development of new drug formulations are further propelling market expansion. However, the presence of generic alternatives and the rise of alternative treatment methods present challenges. Despite these hurdles, growing awareness around the necessity of early diagnosis and efficient treatment is anticipated to significantly enhance market dynamics, fostering continued advancements and adoption of peptic ulcer medications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segments Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

A significant factor propelling the growth of the peptic ulcer drugs market is the rising incidence of peptic ulcers globally. These gastrointestinal disorders impact a vast number of individuals, resulting in an increased need for effective treatment solutions. Contributing elements, such as poor lifestyle choices, heightened stress levels, and the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs), have been linked to the escalated occurrence of peptic ulcers. Consequently, this growing demand for effective medication not only highlights the importance of addressing this health issue but also fosters overall market expansion as healthcare providers seek to meet the needs of affected patients.

Restraints in the Peptic Ulcer Drugs Market

A key limitation facing the global peptic ulcer drugs market is the presence of various alternative treatment options. Many individuals turn to non-pharmacological methods, including lifestyle changes, dietary adjustments, and natural remedies, which are viewed as effective in managing peptic ulcers. This preference for alternatives can reduce the demand for conventional peptic ulcer medications. Additionally, concerns surrounding the potential side effects and health risks linked to prolonged use of these drugs may further deter patients and healthcare providers from relying solely on pharmaceuticals, ultimately affecting market trends and overall growth within the industry.

Market Trends of the Peptic Ulcer Drugs Market

A significant trend in the global peptic ulcer drugs market is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is largely attributed to the superior efficacy and favorable safety profiles of PPIs in comparison to alternative therapies, as they significantly decrease stomach acid production, thereby offering prolonged symptom relief and aiding in ulcer healing. Furthermore, ongoing advancements in drug formulations have enhanced the bioavailability and compliance rates among patients, further solidifying the appeal of PPIs. The growing inclination toward this class of medications is poised to substantially influence demand dynamics within the peptic ulcer drugs market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2026-2033)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations